Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
Veracyte will host an investor call on June 1, 2026, to discuss Phase III clinical trial data for its Prosigna Breast and Decipher Prostate tests. The data from the OPTIMA and ENZAMET trials will be presented at the 2026 ASCO Annual Meeting, marking a key evidence-generation milestone for these diagnostics.
Key figures
- Drug Name
- Prosigna Breast, Decipher Prostate
- Phase Of Trial
- Phase III
- Call date
- June 1, 2026
- Conference
- ASCO Annual Meeting 2026
- Trial names
- ["OPTIMA","ENZAMET"]
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.